| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 06/27/2002 | WO2002050105A1 Novel compounds |
| 06/27/2002 | WO2002050097A2 Anti-allergic complex molecules |
| 06/27/2002 | WO2002050073A1 Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors |
| 06/27/2002 | WO2002050071A1 Thiazolyl inhibitors of tec family tyrosine kinases |
| 06/27/2002 | WO2002050066A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050065A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050043A1 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof |
| 06/27/2002 | WO2002050034A2 Tetracyclic carbazole derivates and their use as spla2 inhibitors |
| 06/27/2002 | WO2002050033A1 Benzo(f) isoindol derivatives and their use as ep4 receptor ligands |
| 06/27/2002 | WO2002050032A1 Naphthalene derivatives which bind to the ep4 receptor |
| 06/27/2002 | WO2002050031A1 Indole derivatives |
| 06/27/2002 | WO2002050029A2 Tetracyclic derivatives as spla2 inhibitors |
| 06/27/2002 | WO2002050028A2 Substituted benzoindoles as spla2 inhibitors |
| 06/27/2002 | WO2002050021A1 Nitric oxide synthase inhibitor phosphate salt |
| 06/27/2002 | WO2002050019A2 Diamines as modulators of chemokine receptor activity |
| 06/27/2002 | WO2002049993A2 High affinity small molecule c5a receptor modulators |
| 06/27/2002 | WO2002049666A2 Mycoplasma hyopneumoniae bacterin vaccine |
| 06/27/2002 | WO2002049660A1 Injectable solution with anti-inflammatory effect and process for manufacturing the same |
| 06/27/2002 | WO2002049655A1 Extracts of piper betle leaves as immunomodulator |
| 06/27/2002 | WO2002049651A1 Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives |
| 06/27/2002 | WO2002049650A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives |
| 06/27/2002 | WO2002049649A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) |
| 06/27/2002 | WO2002049634A2 Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect |
| 06/27/2002 | WO2002049625A2 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
| 06/27/2002 | WO2002030353A3 NF-λB INHIBITORS |
| 06/27/2002 | WO2002026935A3 TGF-β INHIBITORS AND METHODS |
| 06/27/2002 | WO2002022602A3 Triazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002020822A3 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 06/27/2002 | WO2002009752A3 Immunological adjuvant compounds |
| 06/27/2002 | WO2002005844A3 Protein complex serving as a vehicle for orally administerable medicaments |
| 06/27/2002 | WO2001097838A3 Adjuvants and processes to induce a specific type of immune response |
| 06/27/2002 | WO2001097825A3 High molecular weight extracts of convolvulus arvensis (field bindweed) and polygonum convolvulus (wild buckwheat) |
| 06/27/2002 | WO2001092267A3 Dihydropyridine compounds for the inhibition of calcium-influx |
| 06/27/2002 | WO2001087280A3 Means for treating attacks of auto-immune diseases |
| 06/27/2002 | WO2001076600A3 Inhibition of cytokine generation |
| 06/27/2002 | WO2001035994A3 Chitosan induced immunopotentiation |
| 06/27/2002 | WO2001026605A3 Immunosuppressive composition containing il-2 inhibitor and an adenosine deaminase inhibitor |
| 06/27/2002 | US20020082420 Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
| 06/27/2002 | US20020082305 Petrolatum-based nose ointment |
| 06/27/2002 | US20020082292 Agonists of peroxisome proliferator activated receptor (PPAR) alpha and/or gamma |
| 06/27/2002 | US20020082278 Use to treat allergy, nasal congestion, inflammatory and central nervous system-related diseases |
| 06/27/2002 | US20020082272 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 06/27/2002 | US20020082269 Purine-2,6-dione based compounds as receptor binding assay probes and pharmaceuticals; high potency and affinity with water solubility |
| 06/27/2002 | US20020082256 Compounds useful as anti-inflammatory agents |
| 06/27/2002 | US20020082255 Substituted ureas |
| 06/27/2002 | US20020082249 Prodrugs of aspartyle protease inhibitors |
| 06/27/2002 | US20020082246 Prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading enzymes is involved; these include degenerative joint disorders such as osteoarthroses and disorders of connective tissue |
| 06/27/2002 | US20020082234 Novel prokaryotic polynucleotides, polypeptides and their uses |
| 06/27/2002 | US20020082231 Utilizing ratC polypeptides to screen for antibacterial compounds |
| 06/27/2002 | US20020082230 Introducing an antisense oligomer into a cell, allowing the oligomer to hybridize to the mRNA of IL-15, thereby inhibiting the production of IL-15 |
| 06/27/2002 | US20020082217 Synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes |
| 06/27/2002 | US20020082211 Human presenilin variant |
| 06/27/2002 | US20020082205 Human FGF-23 gene and gene expression products |
| 06/27/2002 | US20020081720 Receptor activator of NF-kappaB |
| 06/27/2002 | US20020081665 Composition for use as immunomodulatory and anticarcinogenic agents |
| 06/27/2002 | US20020081623 Chemotactic cytokine |
| 06/27/2002 | US20020081607 Four disulfide core domain-containing (FDCD) polynucleotides, polypeptides, and antibodies |
| 06/27/2002 | US20020081585 Compounds for detection an inflammatory bowel disease |
| 06/27/2002 | US20020081576 Antibodies directed against binding-associated epitopes |
| 06/27/2002 | US20020081329 Matrix of saponin preparation, a sterol, a phospholipid and a metal chelating moeity that can bind a protein or polypeptide |
| 06/27/2002 | US20020081307 Verotoxin b subunit for immunization |
| 06/27/2002 | US20020081296 Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3 and TACI |
| 06/27/2002 | US20020081290 Protein kinase homologs |
| 06/27/2002 | US20020081282 Genetically engineered cell comprising DNA encoding a transmembrane LAG-3 protein (lymphocyte activting gene) on its surface resulting in the protection from graft rejection by a host's immune system |
| 06/27/2002 | US20020081280 Virology and gene therapy; modified fiber knob retains its ability to trimerize and retains its native biosynthesis profile |
| 06/27/2002 | CA2789252A1 Streptococcus pyogenes antigens and corresponding dna fragments |
| 06/27/2002 | CA2433027A1 Nucleic acid-associated proteins |
| 06/27/2002 | CA2433018A1 Thiazolyl inhibitors of tec family tyrosine kinases |
| 06/27/2002 | CA2432908A1 Diamines as modulators of chemokine receptor activity |
| 06/27/2002 | CA2432879A1 Anti-allergic complex molecules |
| 06/27/2002 | CA2432767A1 Signal-1/signal-2 bifunctional peptide inhibitors |
| 06/27/2002 | CA2432760A1 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof |
| 06/27/2002 | CA2432315A1 Methods for the production of multimeric proteins, and related compositions |
| 06/27/2002 | CA2432047A1 Immunogenic glycopeptides, screening, preparation and uses |
| 06/27/2002 | CA2431990A1 Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes |
| 06/27/2002 | CA2431721A1 Tetracyclic derivatives as spla2 inhibitors |
| 06/27/2002 | CA2431446A1 High affinity antibodies |
| 06/27/2002 | CA2431147A1 Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) |
| 06/27/2002 | CA2431139A1 Oxidoreductases |
| 06/27/2002 | CA2431077A1 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives |
| 06/27/2002 | CA2431074A1 Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (1) |
| 06/27/2002 | CA2431028A1 Tetracyclic carbazole derivates and their use as spla2 inhibitors |
| 06/27/2002 | CA2431023A1 Substituted benzoindoles as spla2 inhibitors |
| 06/27/2002 | CA2430918A1 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
| 06/27/2002 | CA2430595A1 Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side-effect |
| 06/27/2002 | CA2406028A1 Method for testing for allergic disease |
| 06/26/2002 | EP1216710A1 The regulation of systemic immune responses utilizing cytokines and antigens |
| 06/26/2002 | EP1216706A2 Enteral composition for stimulating the immune system |
| 06/26/2002 | EP1216299A2 Gene transfer in human lymphocytes using retroviral scfv cell targeting |
| 06/26/2002 | EP1216248A2 Triazolopyrimidine derivatives |
| 06/26/2002 | EP1216247A1 Imidazoimidazoles and triazoles as anti-inflammatory agents |
| 06/26/2002 | EP1216246A1 N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent |
| 06/26/2002 | EP1216245A1 Pharmaceutically active sulfonyl hydrazide derivatives |
| 06/26/2002 | EP1216238A2 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 06/26/2002 | EP1216234A2 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 06/26/2002 | EP1216056A1 Blocking immune response to a foreign antigen using an antagonist which binds to cd20 |
| 06/26/2002 | EP1216047A2 Novel combination of loteprednol and beta2-adrenoceptor agonists |
| 06/26/2002 | EP1216046A2 Novel combination of loteprednol and antihistamines |
| 06/26/2002 | EP1216044A1 Compositions having improved stability |
| 06/26/2002 | EP1216026A1 Compositions of tocol-soluble therapeutics |